Skip to main content

New Concepts and Criteria for Grading Prostate Cancer




TO ACCESS THIS CONTENT FOR FREE, PLEASE ENTER THE COUPON CODE AT CHECKOUT: 
2021GULive

Original release date:
October 21, 2021
Access to this course expires on:  April 21, 2022 at 11:59 PM Pacific Time
CME 2

Course Description
Classification, grading, staging and reporting of GU tumors continue to evolve with the discovery of pathogenic mechanisms and the advent of novel diagnostic tools and therapies. It is imperative for practicing pathologists to keep pace with the important changes in GU tumor pathology in order to produce pathology diagnoses and reports that meet contemporary patient management needs. Examples requiring educational focus are the significant error rate and inter-observer variability in the diagnosis of cribriform carcinoma and intraductal carcinoma of prostate; under-recognition and under-reporting of bladder cancer variants; misclassification of testicular germ cell tumors correlated with drastic revision of WHO 2016 classification; modifications in prostate grading correlative with newly described morphologic changes, new outcome data and adjustment to the modified Gleason grading system; changes in GU tumor staging following publication of the 8th edition of the AJCC Staging guidelines; requisite refinements in cancer reporting to eliminate significant variation, error, and missing relevant elements. This course is a pragmatic exercise in mentoring for advanced learning taught by international experts who reflect USCAP’s gold standard.


Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Distinguish intraductal carcinoma of prostate from urothelial carcinoma involving prostatic ducts and invasive prostatic adenocarcinoma
  • Discuss contemporary prostate cancer grading
  • Describe diagnostic features and reporting of androgen deprivation and radiation effect

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 2  AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Cristina Magi-Galluzzi, MD, PhD

The following IM Coordinator reported no relevant financial relationships: Ming Zhou, MD

The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships:

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. View and print your certificate by clicking here.

Not A Member? Click Here

TO ACCESS THIS CONTENT FOR FREE, PLEASE ENTER THE COUPON CODE AT CHECKOUT: 2021GULive